Monday, November 6, 2017
- 9:00AM-11:00AM
-
Abstract Number: 973
IL-6 and TNF-a Cooperate to Modulate the Cell Cycle of RA-Fibroblast-like Synoviocytes Via Cyclin Dependent Kinase Inhibitors
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster II: Mesenchymal Cells Do React - But How?- 9:00AM-11:00AM
-
Abstract Number: 1730
IL-6 Mediates Activation of Macrophages in Patients with Systemic Sclerosis
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II- 9:00AM-11:00AM
-
Abstract Number: 1325
Immune Responses to Peptides Containing Homocitrulline or Citrulline in the DR4-Transgenic Mouse Model of Rheumatoid Arthritis
Rheumatoid Arthritis – Animal Models Poster II- 9:00AM-11:00AM
-
Abstract Number: 1155
Impact of Adalimumab on Immunosuppressant Use in Patients with Active and Inactive Non-Infectious Intermediate, Posterior, or Pan-Uveitis in the Ongoing Open Label Study: Visual-III
Miscellaneous Rheumatic and Inflammatory Diseases Poster I- 9:00AM-11:00AM
-
Abstract Number: 1422
Impact of Adalimumab on Prednisone Use in Patients with Rheumatoid Arthritis in a Real World Setting – Results from the Corrona Registry
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports- 9:00AM-11:00AM
-
Abstract Number: 1470
Impact of Anti-Drug Antibody and Injection Site Reaction on Efficacy: 24-Week Results from a Phase III Study Comparing SB4 (etanercept biosimilar) with Reference Etanercept in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports- 9:00AM-11:00AM
-
Abstract Number: 1222
Impact of Bariatric Surgery on Bone Mineral Density : Observational Study of 110 Patients Followed up in a Specialised Centre for the Treatment of Obesity in France
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster II- 9:00AM-11:00AM
-
Abstract Number: 1453
Impact of Biological and Targeted Synthetic Dmards on Work in Patients with Chronic Inflammatory Arthritides : A Meta Analysis of Randomized Controlled Trials and Controlled Cohorts
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports- 9:00AM-11:00AM
-
Abstract Number: 1162
Impact of Bone Localization on the Prognostic of Langerhans Cell Histiocytosis: A Monocentric Retrospective Study
Miscellaneous Rheumatic and Inflammatory Diseases Poster I- 9:00AM-11:00AM
-
Abstract Number: 1129
Impact of Diuretics on Urate Lowering Therapy in Patients with Gout: Analysis of an Inception Cohort
Metabolic and Crystal Arthropathies Poster I- 9:00AM-11:00AM
-
Abstract Number: 989
Impact of DMARD Treatment on Risk of Repeat Cardiovascular Events Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1344
Impact of Fibromyalgic RA on Composite Scores; Results from a Longitudinal Study of RA Patients Initiating Bdmard Therapy
Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures- 9:00AM-11:00AM
-
Abstract Number: 1424
Impact of Glucocorticoid Therapy on the Efficacy of SC Abatacept or Adalimumab in RA Patients with Inadequate Response to MTX: A Post Hoc Analysis of Data from a Head-to-Head Trial
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports- 9:00AM-11:00AM
-
Abstract Number: 1038
Impact of Patient Support Program Utilization on Patient Activation Measure Scores Among Patients with Rheumatoid Arthritis